Wedbush Reiterates Outperform on Immunome, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Immunome (NASDAQ:IMNM) and maintained a $33 price target.
August 13, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Immunome (NASDAQ:IMNM) and maintained a $33 price target.
The reiteration of an Outperform rating and the maintenance of a $33 price target by a reputable analyst can boost investor confidence in Immunome, potentially leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100